IP Library › Granted Patent US 9,968,670
Granted Patent B2
US 9,968,670 · App. 14/652,643 · Granted May 15, 2018

Influenza virus vaccines and uses thereof

Inventors: Adolfo Garcia-Sastre (New York, NY); Peter Palese (New York, NY); Florian Krammer (New York, NY)
Assignee: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
A61K39/145A61K39/12C07K14/005C12N7/00A61K2039/521A61K2039/5252A61K2039/54A61K2039/543A61K2039/545A61K2039/55A61K2039/70C12N2760/16123C12N2760/16134C12N2760/16223C12N2760/16234
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,968,670
App. No.
14/652,643
Granted
May 15, 2018
Kind
B2
Abstract

Provided herein are chimeric influenza hemagglutinin (HA) polypeptides, compositions comprising the same, vaccines comprising the same, and methods of their use.

Claims (22)

1. A method of immunizing a subject against an influenza virus comprising:

(a) administering to the subject an effective amount of a first immunogenic composition comprising a first chimeric hemagglutinin (HA) polypeptide, wherein the first chimeric HA polypeptide comprises the stem domain of the HA from influenza virus A/Perth/16/2009 (H3N2) and the globular head domain of the HA from an influenza virus A/Duck/Czech/1956 (H4); and

(b) subsequent to the administration of the first immunogenic composition to the subject, administering to the subject a second immunogenic composition comprising a second chimeric hemagglutinin (HA) polypeptide, wherein the second chimeric HA polypeptide comprises an influenza virus hemagglutinin stem domain and an influenza virus hemagglutinin globular head domain, wherein the influenza virus hemagglutinin globular head domain is heterologous to the influenza virus hemagglutinin stem domain;

and wherein the globular head domain of the first chimeric influenza virus HA polypeptide is different than the globular head domain of the second chimeric HA polypeptide.

2. A method of immunizing a subject against an influenza virus comprising:

(a) administering to the subject an effective amount of a first immunogenic composition comprising a first chimeric hemagglutinin (HA) polypeptide, wherein the first chimeric HA polypeptide comprises an influenza virus hemagglutinin stem domain and an influenza virus hemagglutinin globular head domain, wherein the influenza virus hemagglutinin globular head domain is heterologous to the influenza virus hemagglutinin stem domain; and

(b) subsequent to the administration of the first immunogenic composition to the subject, administering to the subject a second immunogenic composition comprising a second chimeric hemagglutinin (HA) polypeptide, wherein the second chimeric HA polypeptide comprises the stem domain of the HA from influenza virus A/Perth/16/2009 (H3N2) and the globular head domain of the HA from an influenza virus A/Duck/Czech/1956 (H4);

and wherein the globular head domain of the first chimeric influenza virus HA polypeptide is different than the globular head domain of the second chimeric HA polypeptide.

3. The method of claim 1 , wherein the second chimeric HA polypeptide comprises the stem domain of the HA from influenza virus A/California/4/2009 (H1N1) and the globular head domain of the HA from an influenza virus A/Vietnam/1203/2004 (H5), A/Indonesia/5/2005 (H5), A/Anhui/1/2005 (H5), A/Bar headed goose/Quinghai/1A/2005 (H5), A/turkey/Turkey/1/2005 (H5), or A/whooperswan/Mongolia/244/2005 (H5).

4. The method of claim 2 , wherein the first chimeric HA polypeptide comprises the stem domain of the HA from influenza virus A/California/4/2009 (H1N1) and the globular head domain of the HA from an influenza virus A/Vietnam/1203/2004 (H5), A/Indonesia/5/2005 (H5), A/Anhui/1/2005 (H5), A/Bar headed goose/Quinghai/1A/2005 (H5), A/turkey/Turkey/1/2005 (H5), or A/whooperswan/Mongolia/244/2005 (H5).

5. The method of claim 1 , wherein the first immunogenic composition and/or the second immunogenic composition is a multivalent vaccine.

6. The method of claim 2 , wherein the first immunogenic composition and/or second immunogenic composition is a multivalent vaccine.

7. The method of claim 3 , wherein the first immunogenic composition and/or second immunogenic composition is a multivalent vaccine.

8. The method of claim 1 , wherein the first and/or the second chimeric HA polypeptide is part of an inactivated virus or live attenuated virus.

9. The method of claim 2 , wherein the first and/or the second chimeric HA polypeptide is part of an inactivated virus or live attenuated virus.

10. The method of claim 3 , wherein the first and/or the second chimeric HA polypeptide is part of an inactivated virus or live attenuated virus.

11. The method of claim 1 , wherein the subject is human.

12. The method of claim 2 , wherein the subject is human.

13. The method of claim 3 , wherein the subject is human.

14. The method of claim 4 , wherein the first and/or the second immunogenic composition is a multivalent vaccine.

15. The method of claim 4 , wherein the first and/or second chimeric HA polypeptide is part of an inactivated virus or live attenuated virus.

16. The method of claim 4 , wherein the subject is human.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jan 28, 2019
From: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 049649/0675 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 26, 2016
From: GARCIA-SASTRE, ADOLFO; KRAMMER, FLORIAN; PALESE, PETER
To: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
Reel/Frame 038385/0909 →
Continuity (3)
Provisional Application 61840899 · Jun 28, 2013
Provisional Application 61738672 · Dec 18, 2012
Related Publication 20150335729A1 · Nov 26, 2015